The immune landscape of the TH-MYCN tumour following JQ1 treatment showed an increased percentage of CD8+PD-1+, CD4+PD-1+, and Treg PD-1+ cells compared to controls, although it did not affect immune cell infiltration to the TME. This evidence concerns the gene CD8A and neoplasm.